A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
The group could soon provide clarity on CTX112’s regulatory path.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
Boehringer discontinues brigimadlin while others continue to struggle.
The THIO-104 study listing is live, along with questions about funding the trial.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
